← Leaderboards
Leslie Philip Weiner
University Of Southern California
$6,552,756
Attributed
$6,552,756
Total exposure
5
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $752.3K · FY2005–06$1M$750K$500K$250K$0
'05
'06
Funding mix
By agency
NIH$6,552,756 · 5
By mechanism
R01$3,977,843 · 1
M01$1,697,127 · 2
K12$479,248 · 1
P01$398,538 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Southern California
Same institution · by research overlap
- Don J Diamond$24,317,616
- Harry V. Vinters$7,164,202
- Nunzio Bottini$23,475,201
- David A Horwitz$3,172,796
- Dominique Duncan$3,859,074
Others in their field
Top investigators on “T Lymphocyte”
- Barton F Haynes · Duke University$408,040,925
- Lawrence Corey · Fred Hutchinson Cancer Center$299,247,526
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$157,640,776
- Dan H. Barouch · Fred Hutchinson Cancer Center$139,062,963
- James Dennis Neaton · Northwestern University$107,288,548
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$83,920,398
Research focus
T LymphocyteMultiple SclerosisHuman SubjectClinical ResearchHuman Therapy EvaluationVaccinesMagnetic Resonance ImagingImmunotherapyCytokineMyelinClinical Trial Phase IImmunopathology TherapyVaccine DevelopmentLeukocyte Activation /TransformationCellular ImmunityNervous System Disorder ChemotherapyCell TransplantationPathologic ProcessClinical Trial Phase IiMonoclonal AntibodyImmunocytochemistryAntigen Antibody ReactionHybridomasHelper T Lymphocyte
Grant awards (22)
T CELL VACCINATION: A CLINICAL TRIAL FOR SECONDARY PROGRESSIVE MS$29,395
M01 · FY2006 · RR · contact PI
T-Cell Vaccine-A Clinical Trail for Progressive MS$545,659
R01 · FY2005 · NS
T CELL VACCINATION: A CLINICAL TRIAL FOR SECONDARY PROGRESSIVE MS$206,593
M01 · FY2005 · RR
T Cell Vaccination: A Clinical Trial for MS$1,269,822
M01 · FY2004 · RR
T-Cell Vaccine-A Clinical Trail for Progressive MS$658,481
R01 · FY2004 · NS
T-Cell Vaccine-A Clinical Trail for Progressive MS$975,900
R01 · FY2003 · NS
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS$388,797
R01 · FY2002 · NS
CORE--NEUROPATHOLOGY FACILITY$106,204
P01 · FY2002 · NS
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS$82,500
R01 · FY2002 · NS
T CELL VACCINATION IN MULTIPLE SCLEROSIS--PHASE I CLINICAL TRIAL$0
M01 · FY2002 · RR
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS$604,010
R01 · FY2001 · NS
T CELL VACCINATION IN MULTIPLE SCLEROSIS--PHASE I CLINICAL TRIAL$155,764
M01 · FY2001 · RR
CORE--NEUROPATHOLOGY FACILITY$106,204
P01 · FY2001 · NS
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS$81,368
R01 · FY2001 · NS
T CELL VACCINATION IN MULTIPLE SCLEROSIS--PHASE I CLINICAL TRIAL$0
M01 · FY2001 · RR
T CELL VACCINE--A CLINICAL TRIAL FOR PROGRESSIVE MS$641,128
R01 · FY2000 · NS
MCSDPA--NEUROGERONTOLOGY$479,248
K12 · FY2000 · AG
CORE--NEUROPATHOLOGY FACILITY$186,130
P01 · FY2000 · NS
T CELL VACCINATION IN MULTIPLE SCLEROSIS--PHASE I CLINICAL TRIAL$35,553
M01 · FY2000 · RR
T CELL VACCINATION: CLINICAL TRIAL FOR SECONDARY MS$0
M01 · FY2000 · RR
T CELL VACCINATION IN MULTIPLE SCLEROSIS--PHASE I CLINICAL TRIAL$0
M01 · FY2000 · RR
T CELL VACCINATION: CLINICAL TRIAL FOR SECONDARY MS$0
M01 · FY2000 · RR